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Summary 
Poly- and oligodonal T cell stimuli like anti-CD3e monoclonal antibody or Staphylococcus aureus 
enterotoxin B (SEB), injected at doses that per se are not lethal, provoke acute death within 
less than 24 h, provided that endogenous glucocorticoids (GC) are depleted by adrenalectomy 
or by injection of saturating amounts of the GC receptor antagonist RU-38486 (mifepristone). 
Pharmacological doses of the GC agonist dexamethasone (DEX) alter the in vivo response of 
splenic V38 + T cells to SEB, thus impeding the expansion of such cells and causing their rapid 
(3 d) clonal deletion. In contrast, coadministration of RU-38486 counteracts a SEB-induced early 
(12 h) reduction of V38+CD4 + and V38+CD8 + spleen cells. In vivo T  cell stimulation by 
injection of bacterial superantigen induces a rapid (peak at 90-120 rain) increase in corticosterone 
serum levels, suggesting that endogenous GC might control early T cell activation.  Accordingly, 
kinetic studies revealed that RU-38486 has to be administered within 2 h after  superantigen 
administration to exert its lethal effect. Similarly, exogenous GC must be injected during this 
critical  phase (2 h)  to rescue animals  from acute death induced by coinjection of SEB and 
D-galactosamine  (GAIN). Adrenalectomy, injection of RU-38486 and priming with GaIN per 
se provoke the programmed death of peripheral CD4 + and CD8 + T cells. Thus, three manipu- 
lations that sensitize mice for the lethal effect of T  cell stimulation also exert  a proapoptotic 
effect on peripheral T cells. In synthesis, endogenous and exogenous GC regulate T cell responses 
and determine the propensity of peripheral T  cells to undergo apoptosis. 
S 
Ynthetic  glucocorticoid  (GC) 1 agonists  are  used  for 
therapy of a broad spectrum of organ-specific and gener- 
alized autoimmune diseases. In the same way, endogenous 
GC secreted by the adrenal glands may act as immunosup- 
pressive  and  antiinflammatory  agents  that  contend  life- 
threatening overreactions  of the immune system, as well as 
autoaggressive responses (for reviews see references 1, 2). GC 
inhibit macrophage functions, including cytotoxic functions, 
processing, and presentation of antigen to T cells, inhibit the 
production of IL-2 and IFN-3, in T  lymphocytes (3),  shift 
T cell responses from the Thl to the Th2 type (4), decrease 
the activity of NK cells, induce programmed cell death in 
a variety of different immunologically  relevant cells, including 
immature T and B cell precursors (for reviews see references 
5, 6) and mature T cells (7), and inhibit the synthesis of a 
variety of proimflammatory  cytokines (IL-1, IL-6, and TNF-o  0 
(8). Immune activation frequently is associated with an in- 
* Abbreviations used in this paper: CN, corticosterone; CsA, cyclosporine 
A; DEX, de~camethasone; GAIN, D-galactosamine; GC, glucocorticoid; 
SEA~B, Staphylococcus  aureus  enterotoxin  A/B; PCD, programmed  cell  death. 
crease in ACTH and GC secretion,  and the susceptibility of 
certain animal strains to develop autoimmune diseases is linked 
to a deficient GC-mediated inhibition of immune function 
(2,  9-12). 
Recently, a synthetic steroid, KU-38486 (RU486, mifepris- 
tone), with potent antiprogestational and antiglucocorticoid 
activity has become available for clinical use as an abortifa- 
cient agent (13, 14) and for treatment of gestagen-dependent 
tumors and hypercortisolism (15). In the present study, we 
investigated the effect of RU-38486 on T cell activation in 
vivo. It is shown that RU-38486, present during the acute 
phase of T cell stimulation, dramatically enhances the lethality 
of in vivo T  cell activation.  Evidence is presented that ad- 
ministration of T cell activators provokes an acute transient 
release of corticosterone (CN) into the circulation. Adminis- 
tration of GC reduces the toxicity of T cell activation, while 
preventing the antigen-driven expansion and accelerating the 
deletion of the specific T cell subset.  The data presented in 
this report support the contention that (endogenous) GC in- 
tervene in the regulation of the activation, expansion, antigen- 
specific deletion, and programmed cell death of peripheral 
T  cells in vivo. 
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Animals and In Vivo Treatment.  Male  8-10-wk-old BALB/c mice 
were obtained from the local animal housing facility (Centro de 
Biologla Molecular, CSIC,  Madrid),  whereas  adrenalectomized 
BALB/c mice (maintained with 0.9% NaC1 in the drinking water) 
and sham-operated BALB/c controls were obtained from a com- 
mercial source (Charles River, Lyon, France). Animals received  in- 
jections of Staphylococcus aureus enterotoxin B (SEB) (Sigma Im- 
munochemicals, St. Louis, MO), SEA (Sigma Immunochemicals), 
mAbs directed against CD3e (145.Cll; 16) or V/38 (F23.1 that recog- 
nizes V/~8.1, VB8.2, and VBS.3; 17), RU-38486 (Roussel Uclaf, 
Romainville, France, kindly provided by Dr. Martini),  cyclospo- 
rine A (CsA) (Sandoz, Basel, Switzerland), D-galactosamine  (GAIN) 
or dexamethasone  (DEX; Sigma Immunochemicals). These reagents 
were suspended in 200 #1 PBS and were injected either intrave- 
nously or intraperitoneally  at the indicated dose. In one series of 
experiments, blood was taken 120 min after the injection of SEB, 
and corticosterone (CN) concentrations were determined by means 
of a commercial RIA (ICN Biomedicals, Inc, Costa Mesa, CA). 
Immunofluorescence Analysis.  Splenic  monocellular cell suspen- 
sions were subjected to hypotonic erythrocyte lysis, washed and 
stained with mAbs directed against CD4 (HK1.5; Becton Dick- 
inson & Co., Mountain View, CA), CD8 (H02.2), Vi56 (RR4-7; 
17), or V/38 (F23.1; 18) which were either FITC labeled or biotin 
conjugated and developed  by means of streptavidin-PE as described 
(19, 20). 
Assessment ofApoptotic DNA Fragmentation.  CD3 +, CD4 ÷ or 
CD8 ÷ splenic T cells were prepared by negative selection using 
columns (Cellect~'; Biotex, Edmonton, Canada). Contamination 
with slg ÷, CD8 +, or CD4 ÷ cells was <1% for CD3 ÷, CD4 +, 
and CD8 ÷ T cells, respectively. After a brief in vitro culture (2 h 
at 37°C in RPMI 1640 supplemented with 10% FCS), 2  x  106 
cells were washed, pelleted, and incubated at 50% in 20 #1 of 10 
mM EDTA, 50 mM Tris-HC1, 0.5% sodium laurylsarkosinate, and 
0.5/zg/ml protease K, followed  by the addition of 10 gl of 10/zg/ml 
RNase A,  incubation  for 1 h at 37°C, and electrophoresis over 
a 1.2% gel containing 0.1/xg/ml ethidium bromide, as described 
(20,  21). 
Results and Discussion 
Endogenous GC Protect Mice against the Lethal Effect of  Acute 
T Cell Activation In Vivo.  Normal BALB/c mice do not suc- 
cumb to doses as high as 250 gg of the CD3E-specific mAb 
145-Cll, an antibody that induces a cytokine release syndrome 
via the nonspecific polyclonal stimulation oft cells (22). How- 
ever, two manipulations sensitize to the lethal effect of anti- 
CD3, namely coinjection of the monosaccharide GaIN (22) 
and coinjection of the GC antagonist RU-38486 (Table 1), 
an agent that has been previously shown to sensitize mice 
to the lethal effect of TNF (23), one of the major intermediate 
effector molecules of polyclonal T cell stimulation (22, 24). 
The ED50 of otCD3 combined with GaiN (*2.5 #g otCD3) 
is lower than that of otCD3 combined with RU-38486 (>10 
/zg otCD3). The sensitizing effect of the anti-GC RU-38486 
is abolished by coadministration of DEX and is not restricted 
to otCD3, but also concerns the superantigen SEB, which 
specifically stimulates Vj58 + T  cells (about 30% of CD3 + 
T  cells in BALB/c mice). The toxic effect of SEB requires 
the presence of large numbers of superantigen-reactive V/38 + 
T cells (25). Accordingly, SEA (which stimulates V/33 + and 
V~ll + T  cells)  is not toxic for BALB/c mice that contain 
<1% of SEA-reactive V/33 + or V/811 + cells among periph- 
eral lymphocytes (but kills GaiN-sensitized C57/B16 mice 
that contain >10% VB3 + plus V/311 + T  cells). Surprisingly, 
the VB8-specific antibody F23.1 was not capable of killing 
GAIN- or RU-38486-sensitized BALB/c mice (Table 1), indi- 
cating that the mode of stimulation exerted by this antibody 
must differ from that of the equally V~8-specific superan- 
tigen SEB. Accordingly, the signal transduction cascades trig- 
gered by superantigens and conventional stimuli exhibit an 
only partial overlap in vitro (26, 27). Moreover, F23.1 differs 
from SEB in the sense that its in vitro application fails to 
trigger an expansion of V/% + T  cells but rather provokes 
an immediate programmed cell death-mediated depletion of 
V/38 + T  cells  (data not shown). 
Since pharmacological doses of RU-38486 might have GC- 
agonistic and nonspecific toxic effects (28), we tested whether 
adrenalectomy also  would predispose BALB/c mice to the 
lethal effect of SEB. Indeed, adrenalectomy with the subse- 
quent decrease in endogenous GC level rendered animals sus- 
ceptible to the acute lethal effect of SEB. This phenomenon 
was readily reverted by administration of low doses of DEX 
(Table 1). Thus, endogenous GC control the acute response 
to T  cell stimulation in vivo, and the effect of RU-38486 
can be attributed to the blockade of GC receptors. 
Mutual Interaction between the Immune and the GC Systems 
during a Critical Phase of Several Hours.  As shown in Fig.  1, 
the injection of SEB induces an increase in circulating CN 
levels by at least one order of magnitude over the baseline 
(peak at 90-120 rain). This increase in plasma CN drops off 
within 6 h after injection. The CN response induced by SEB 
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Figure 1.  CN serum levels  after  injection  of SEB alone  or in combina- 
tion with several immunomodulators. BALB/c  mice received  injections 
(black squares) ofS. aureus enterotoxin  B (SEB; 50/xg  i.v.), D-galactosamine 
(NGal, 20 mg i.p.), RU-38486 (10 mg i.p. at the same time) dexametha- 
sone (DEX, 1 mg, 2 h before SEB), or were primed with SEB (50 #g 
i.v. 6 h before the second injection of SEB). (White boxes) Appropriate 
PBS controls. After 2 h, animals were killed by cervical  dislocation and 
heart blood was immediately  removed. CN serum levels (three to four 
animals per group) were measured by KIA. 
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Toxin  Sensitizing  agent  Percent mortality 
(Intravenous doses)  (Intraperitoneal doses)  (Deaths/total) 
None  10 mg RU486"  0  (0/5) 
None  20 mg GaIN  0  (0/6) 
250/~g  ~x CD3  None  0  (0/6) 
100  #g c~ CD3  10 mg RU486  100  (6/6) 
50 #g a  CD3  10 mg RU486  100  (6/6) 
50#gaCD3  10mgRU486  +  lmgDEX  0(0/5) 
25  #g a  CD3  10 mg RU486  100  (3/3) 
10/zg a  CD3  10 mg RU486  0  (0/3) 
5 #g a  CD3  10 mg RU486  0  (0/3) 
25  /~g o~ CD3  20 mg GaIN  100  (3/3) 
10/~g a  CD3  20 mg GaiN  100  (6/6) 
5 /zg cr CD3  20 mg GaIN  100  (6/6) 
2.5  #g a  CD3  20 mg GaiN  67 (2/3) 
1 /zg a  CD3  20 mg GaIN  0  (0/6) 
500/zg  SEB  None  0  (0/3) 
100/zg  SEB  None  0  (0/5) 
100/zg  SEB  Sham-operated  0  (0/5) 
100/zg  SEB  Adrenalectomized  100  (5/5) 
100  #g SEB  Adrenalectomized  +  DEX*  0  (0/5) 
100  #g SEB  10 mg RU486  100  (5/5) 
50/zg  SEB  10 mg RU486  100  (5/5) 
50 #g SEB  5 mg RU486  25  (2/8) 
50/zg SEB  1 mg RU486  0  (0/5) 
50/zg  SEB  10 mg RU486  +  1 mg DEX  0  (0/5) 
25  #g SEB  10  mg RU486  67  (2/3) 
10/zg  SEB  10 mg RU486  0  (0/6) 
50/zg  SEB  20 mg GaIN  100  (6/6) 
100 #g SEA  None  0  (0/6) 
100  /zg SEA  10 mg RU486  0  (0/6) 
100  #g SEA  20 mg GaIN  0  (0/6) 
250/~g  c~ V/38  None  0  (0/6) 
250/zg  cr V/38  10 mg RU486  0  (0/6) 
250 #g o~ V/38  20 mg GaiN  0  (0/3) 
8-10-wk-old  male BALB/c mice received the simultaneous injection of T cell-targeted  stimuli (intravenously via the tail vein) and the indicated 
sensitizing agent (intraperitoneally) suspended in 200/zl PBS. Death rates were monitored during the following 5 d. In all cases, animals died within 
an interval of 12-48 h after experimental manipulation. 
* RU486,  RU-38486. 
* Animals that had been adrenalectomized 5 d before received two t0/zg i.p.  injections of DEX 6 and 2 h before injection of SEB. 
was increased in the presence of RU-38486,  but was com- 
pletely prevented by pretreatment  of animals with DEX  (1 
mg i.p. 2 h  before the injection of SEB), suggesting the ac- 
tion of a GC-mediated feedback inhibition  of the immune- 
stimulated  CN  release (1,  29).  Injection  of SEB  into  mice 
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that had been primed 6 h  earlier with SEB, a manipulation 
that leads to an exhaustion of T  cell function and lymphokine 
release (30), fails to increment the level of plasma CN. GaIN 
did not modulate the SEB-induced CN response, thus indi- 
cating that its mode of action differs from that of RU-38486. A 
RU-38486  together  with  SEB  RU.38486  1  hour  after  SEB 
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Figure 2.  Effect  of GC antagonists and agonists on SEB 
toxicity in vivo. (.4) Effect of the anti-GC RU-38486 on 
SEB challenge. BALB/c  mice received  50/~g SEB i.v. (0 h) 
followed by intraperitoneal injection of 10 mg RU-38486 
0-4 h after SEB. Survival  was monitored at 12, 18, 24, 48, 
and 96 h. (B) Effect of DEX on challenge with SEB plus 
D-galactosamine. DEX (1 mg i.p.) was given  2 h before  and 
up to 4 h after the challenge with SEB (50/~g i.v.) plus 
D-galactosamine (20 mg i.p., given simultaneously with 
SEB). Dying animals exhibited hypothermia, pilierection, 
and diarrhea. 
To test whether  the SEB-triggered  short-term  elevation 
of CN is relevant to the outcome of SEB responses in vivo, 
the GC antagonist RU-38486 and the GC superagonist DEX 
were injected at different intervals into mice challenged with 
SEB. RU-38486 only increased the susceptibility to the le- 
thal effect of SEB when given within  2 h  after SEB chal- 
lenge. Application of RU-38486 after 4 h failed to provoke 
death (Fig.  2 A). Along the same line, DEX only was effec- 
tive in preventing the acute death of mice receiving simul- 
taneous treatment with SEB and GAIN, when administered 
within 2 h (Fig.  2 B). These observations suggest the physi- 
ological relevance  of acute short-term  elevations of GC in 
the regulation  of the immune  response. 
Effect of GC on Superantigen-induced Clonal Expansion and 
Deletion of Peripheral T Cells.  In vivo injection of SEB en- 
tails  a phase  of donas  expansion  of VB8 + T  ceils (maxi- 
mum, 2-3 d), followed by a phase of clonal deletion (mini- 
mum,  10 d). These changes affect both the CD4 + and the 
CD8 + subsets (20, 21, 31, 32). To test the possible effect of 
endogenous GC on the SEB-driven sequential expansion and 
contraction  of V/~8 + T  cells,  RU-38486 was administered 
to mice 4 h subsequent to the SEB challenge (as in Fig. 2), 
followed by two daily injections of RU-38486 throughout 
the experiment. This should be suffident to reduce the effect 
of endogenous GC, as RU-38486 saturates the GC receptor 
within 1 h after in vivo administration and inhibits the tran- 
scription of GC-inducible genes for several hours (15,  33). 
Moreover, the fact that this protocol of RU-38486 adminis- 
tration and surgical adrenalectomy have similar effects in other 
experimental  systems (vide infra) suggests that the GC receptor 
blockade is rather complete.  In spite of this manipulation, 
no significant changes in the SEB-modulated expression of 
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Figure  3.  Modulation of the frequency of V/58  + T cells by SEB in con- 
junction with RU-38486 (RU486) (A and B) and dexamethasone (DEX) 
(B).  2 or 10 d subsequent  to the injection  of SEB (50/zg i.v.), the fre- 
quency of V/38  + T cells among CD4 + (left) or CD8 * (right) splenic T 
cells was determined  by FACS  |  analysis as described in Materials  and 
Methods. RU-38486 (10 mg i.p.) was administered starting from 4 h after 
SEB (50 #g i.v.) challenge, and then reinjected every 12 h (A). Alterna- 
tively, the frequency of V138  § T  cells was assessed 12 h subsequent  to 
SEB injection, and RU-38486 was injected once either together with SEB 
or 4 h later (B). In a further experiment,  V~38  + T cells DEX (1 mg i.p.) 
was given 2 h before the injection  of SEB and was repeated once 24 h 
later  (C).  PBS served as vehicle control for RU-38486 and DEX injec- 
tions, respectively. Mean values _+ SEM for three to six animals are given. 
Data are representative for three  independent  experiments. 
after 2 d  (Fig. 3 A). This acute, transient,  previously un- 
described drop in V38+CD4 + and V38+CD8 + cells appar- 
ently is GC dependent, since it is fully abolished by coad- 
ministration of RU-38486.  No such effects were observed 
when RU-38486  was given 4 h after SEB (Fig. 3 B), thus 
underlining the probable role of the GC elevation over base- 
line levels that immediately follows SEB injection. 
High doses of  exogenous GC present during the early phase 
of the SEB response provoke a major alteration  in the be- 
havior of the V38 + subset. Instead of exhibiting an expan- 
sion of VB8 + T cells, DEX-treated animals display a highly 
significant rapid deletion of V38 + T cells that can be well 
V38 among total T  cells was detected as compared to vehicle- 
injected controls (Fig. 3 A), indicating that baseline GC levels 
are not important  for the regulation of clonal expansion and 
deletion. 
Since RU-38486 coadministered with SEB is lethal within 
24  h  (Fig.  2 A),  it  cannot  be determined  whether  the  GC 
peak after SEB injection (Fig.  1) is relevant  to the regulation 
of SEB  responses  that  become  detectable  several  days  after 
SEB.  We therefore evaluated the consequences of SEB injec- 
tion on the repertoire  of splenic T  cells within  a shorter in- 
terval. 4-8 h  after intravenous administration  of SEB the per- 
centage of VB8 + T  cells begins to decline (data not shown) 
to reach significantly reduced levels after 12 h  (Fig. 3 B), i.e., 
before  the  expansion  of V38 +  cells  that  is  well  detectable 
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Figure  4.  Impact of RU-38486 on the programmed cell death of splenic 
T cells. (A) Effect on splenic and thymic cellularity. Groups of age-matched 
RALB/c mice received injections of saturating  amounts of R.U-38496 (10 
mg i.p.) in 12-h intervals, followed by determination  of the overall cel- 
lularity (viable cells), expressed as the percentage of vehicle-injected con- 
trols.  (B) DNA fragmentation  patterns  of purified  CD3 +,  CD4 +  ,  or 
CD8 + splenic T cells. Cells were recovered from animals that had been 
treated  for 1-5 d with RU-38486 (20 mg i.p./d in 2 doses), adrenalec- 
tomized (AX; or sham operated) 5 d before, or that had been treated by 
injection  of o-galactosamine  (GAIN, 20 mg i.p.). detected 2-3 d after SEB challenge (Fig. 3 B). This in vivo 
finding contrasts with in vitro data that show that GC actu- 
ally inhibit the CD3-stimulated activation cell death of T 
cell hybridomas (34) and thymocytes (35). It remains to be 
determined whether these discrepancies are due to rather dis- 
parate experimental systems (in vivo versus in vitro) or must 
be attributed to the nature of the trigger targeted to the TCR 
(olCD3 versus superantigen).  Although reminiscent of the 
effect of CsA, which also may enhance the SEB-driven dele- 
tion of VB8 + T cells (36), DEX is much more efficient in 
this system, revealing its prodeletional effect after one single 
injection of SEB, whereas the effect of CsA is only observed 
after several rounds of SEB treatment (36). 
Withdrawal of  Endogenous GC Induces Programmed Cell Death 
of Peripheral T Cells.  Shortly after treatment with RU-38486, 
the cellularity of the thymus and the spleen increases by up 
to 100%, reaching its maximum 48 h after the initiation of 
RU-38486 injections in 12-h intervals (Fig. 4 A). Simultane- 
ously, the oligonucleosomal DNA fragmentation pattern typ- 
ical of programmed cell death becomes detectable among 
splenic T cells (Fig. 4 B). Whereas vehicle controls do not 
show signs of apoptosis, peripheral T cells from RU-38486 
treated mice display a DNA fragmentation that increases  with 
the duration of RU-38486  exposure and is accompanied by 
a relative depletion of splenic T cells and thymocytes. DNA 
fragmentation was also observed in adrenalectomized mice. 
This  phenomenon concerned both  CD4 +  and  CD8 §  T 
cells. Surprisingly, GaIN per se also induced PCD of purified 
CD3 + splenic T cells,  (Fig. 4 B). Thus, two manipulations 
that sensitize mice to the lethal effect of T cell-targeted poly- 
clonal stimuli, withdrawal of endogenous GC, and injection 
of GAIN, per se induce apoptosis in peripheral T cells. Whether 
a massive apoptotic decay of lymphocytes contributes to the 
lethal effect of polyclonal stimuli, however, remains to be elu- 
cidated. In this context, it appears intriguing that the im- 
munomodulator linomide, a substance that displays a marked 
antiapoptotic  effect on peripheral T lymphocytes, also coun- 
teracts the lethal effect of bacterial endotoxins and exotoxins 
in vivo (Gonzalo, J. A., A. Gonz~lez-Garch, T. Kalland, G. 
Hedlund, C. Martfnez-A., and G. Kroemer, manuscript sub- 
mitted for publication). 
Concluding Remarks.  As shown in this article, endoge- 
nous GC are involved in the regulation of the cellularity of 
lymphoid organs, programmed cell death of peripheral T cells, 
and specific superantigen responses. Mice treated with RU- 
38486 become susceptible to the fatal effect of T  cell-tar- 
geted stimuli, anti-CD3e, and superantigen, i.e., substances 
that are not lethal per se and act via the stimulation of lym- 
phokine release in T cells (22, 24, 25). It has been shown 
previously that adrenalectomy enhances the mortality pro- 
voked by injection of other agents mimicking septic shock, 
namely LPS, TNF, and IL-1 (37). Like SEB (Fig. 2), LPS, 
IL-1, and TNF are potent inducers of GC in vivo (1, 38). 
Thus, GC produced during acute immune stimulation may 
constitute an important feedback mechanism for contending 
the potentially lethal hyperactivation of the immune system. 
Accordingly, the presence of RU-38486  early after SEB in- 
jection, when endogenous GC rise over baseline levels, will 
have fatal consequences and interfere  with  the SEB/GC- 
driven reduction of VB8 + T cells. If these data were to be 
extrapolated to the human system, the treatment of persons 
at risk of sepsis with the antiglucocorticoid RU-38486 should 
be avoided. 
A further potentially important observation concerns the 
kinetics with which exogenous GC will exert beneficial  effects 
in this model of septic shock. To prevent acute death, GC 
have to be applied early after providing a polyclonal stimulus, 
i.e., within a few hours, thus mimicking the kinetics of en- 
dogenous GC elevation. This may be related to the fact that 
some critical events occur early after stimulation,  e.g., the 
massive, GC-inhibitable secretion of TNF (22, 24), and might 
explain why patients with established  septic shock will scarcely 
profit  from (late) GC medication (39). 
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